Medimmune announced last week that the US FDA has approved its newly constructed influenza vaccine manufacturing facility in England, enabling them to to produce up to 15 million bulk doses per month, or approximately 90 million bulk doses per influenza manufacturing season, of its trivalent, intranasal influenza vaccine, FluMist (Influenza Virus Vaccine Live, Attenuated).

Additionally, the plant will be used to manufacture its investigational flu vaccine, CAIV-T, as well as year-round vaccine production in case of a flu pandemic.

Source: MedImmune